Control Bionics

Control Bionics Earnings Yield

The Earnings Yield of Control Bionics (CBL.AX) as of Nov 21, 2026 is -26.48 %. In the previous year, Earnings Yield was -25.63 % — a change of 3.30% (lower).

Earnings Yield

-26.48 %

YoY

3.30%

Last updated:

Earnings Yield of Control Bionics is 2025 -26.48 % . Earnings Yield of Control Bionics was 2024 -25.63 % . It decreases by 3.30% lower compared to the previous year.

The Control Bionics Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-4.22 AUD
Jan 1, 2019
-8.37 AUD
Jan 1, 2020
-4.36 AUD
Jan 1, 2021
-15.39 AUD
Jan 1, 2022
-26.45 AUD
Jan 1, 2023
-24.41 AUD
Jan 1, 2024
-25.63 AUD
Jan 1, 2025
-26.48 AUD
The Control Bionics Earnings Yield history
YEAREarnings YieldYoY
-26.48 %+3.30%
-25.63 %+5.02%
-24.41 %-7.71%
-26.45 %+71.83%
-15.39 %+253.14%
-4.36 %-47.95%
-8.37 %+98.63%
-4.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Control Bionics Stock analysis

What does Control Bionics do? Control Bionics Ltd. generates revenue through the sale of its NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE systems, which are designed for patients with communication impairments due to conditions like motor neuron disease and amyotrophic lateral sclerosis. The company's NeuroNode technology detects brain signals to skeletal muscles, converting them into EMG output that enables wireless communication via personal computers for speech, email, and texting. Its products integrate with eye-gaze technology, allowing cursor movement on screens as a mouse alternative, with the NeuroNode functioning as the mouse button. These systems are primarily purchased by healthcare providers and rehabilitation centers serving patients with severe motor disabilities. The company's core products include NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE, each tailored to specific communication and mobility needs. NeuroNode Trilogy and NeuroNode Duo focus on EMG-based communication, while Eye-gaze Duo combines eye-tracking with the NeuroNode for cursor control. DROVE is another core system that supports additional functionalities. Healthcare institutions and rehabilitation facilities are the primary buyers, as they deploy these technologies to assist patients with conditions such as motor neuron disease and amyotrophic lateral sclerosis who require augmentative and alternative communication solutions. Control Bionics Ltd. targets medical and rehabilitation sectors, specifically those dealing with patients suffering from motor neuron disease, amyotrophic lateral sclerosis, and similar conditions. The NeuroNode technology is sold as a complete system, including wireless wearable devices and integration with eye-gaze systems, to enable seamless communication through computer-controlled functions. Revenue is derived from direct sales of these systems to healthcare providers who serve individuals with compromised verbal and text-based communication abilities. Control Bionics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Control Bionics stock

Earnings Yield of Control Bionics is -26.48 % in 2025.

Earnings Yield of Control Bionics changed from -25.63 % to -26.48 %, representing a 3.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Control Bionics since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Control Bionics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Control Bionics

All Key Metrics — Control Bionics